Data / Drug companies / Iron Chelator
Iron Chelator drugs: 4 drugs from 30 companies in the FDA NDC directory
Iron Chelator is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 113 products in this class from 30 companies, covering 4 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on August 12, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 30Companies
- 113Products
- 4Drugs by generic name
Drugs in the Iron Chelator class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Deferasirox | 91 | 21 |
| Deferoxamine mesylate | 9 | 6 |
| Deferiprone | 10 | 5 |
| Deferasirox oral | 3 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 10 | tablet, film coated; tablet, for suspension | New drug applications (NDA) | May 18, 2017 |
| Ascend Laboratories, LLC | 9 | tablet, film coated; tablet, for suspension | Generic drugs (ANDA) | July 16, 2020 |
| Alembic Pharmaceuticals Inc. | 6 | tablet, for suspension; tablet, film coated | Generic drugs (ANDA) | June 15, 2020 |
| Alembic Pharmaceuticals Limited | 6 | tablet, for suspension; tablet, film coated | Generic drugs (ANDA) | June 15, 2020 |
| Aurobindo Pharma Limited | 6 | granule; tablet, film coated | Generic drugs (ANDA) | September 8, 2025 |
| Camber Pharmaceuticals, Inc. | 6 | granule; tablet, film coated | Generic drugs (ANDA) | March 16, 2023 |
| Dr. Reddy's Laboratories Inc. | 6 | tablet; tablet, for suspension | Generic drugs (ANDA) | June 25, 2020 |
| MSN Laboratories Private Limited | 6 | tablet, for suspension; tablet | Generic drugs (ANDA) | June 16, 2020 |
| Novadoz Pharmaceuticals LLC | 6 | granule; tablet, for suspension | Generic drugs (ANDA) | May 21, 2022 |
| Amneal Pharmaceuticals NY LLC | 3 | tablet, film coated | Generic drugs (ANDA) | June 15, 2020 |
| Bionpharma Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | September 28, 2018 |
| Chiesi USA, Inc. | 3 | solution; tablet | New drug applications (NDA) | May 19, 2020 |
| Cipla USA Inc. | 3 | granule | Generic drugs (ANDA) | February 23, 2022 |
| Epic Pharma, LLC | 3 | granule | Generic drugs (ANDA) | October 6, 2022 |
| Glenmark Pharmaceuticals Inc., USA | 3 | tablet, for suspension | Generic drugs (ANDA) | January 6, 2020 |
| NorthStar RxLLC | 3 | tablet, film coated | Generic drugs (ANDA) | October 16, 2023 |
| Sun Pharmaceutical Industries, Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | December 2, 2019 |
| Teva Pharmaceuticals, Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | November 1, 2024 |
| Xiromed, LLC | 3 | tablet | Generic drugs (ANDA) | June 15, 2020 |
| Zydus Lifesciences Limited | 3 | tablet, film coated | Generic drugs (ANDA) | June 16, 2020 |
| Zydus Pharmaceuticals USA Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | June 16, 2020 |
| Apotex Corp. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | November 5, 2021 |
| AvKARE | 2 | tablet | Generic drugs (ANDA) | August 12, 2026 |
| Dr. Reddy's Laboratories Inc. | 2 | tablet, coated | Generic drugs (ANDA) | December 15, 2025 |
| Fresenius Kabi USA, LLC | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 15, 2009 |
| Gland Pharma Limited | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 9, 2017 |
| Hikma Pharmaceuticals USA Inc. | 2 | tablet, coated | Generic drugs (ANDA) | February 8, 2022 |
| Sun Pharmaceutical Industries, Inc. | 2 | tablet | Generic drugs (ANDA) | February 5, 2024 |
| Hospira, Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | March 31, 2005 |
| Mitem Pharma | 1 | injection, powder, for solution | New drug applications (NDA) | April 2, 1968 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, for suspension | 33 | 29.2% |
| Tablet, film coated | 31 | 27.4% |
| Granule | 21 | 18.6% |
| Tablet | 14 | 12.4% |
| Injection, powder, lyophilized, for solution | 8 | 7.1% |
| Tablet, coated | 4 | 3.5% |
| Injection, powder, for solution | 1 | 0.9% |
| Solution | 1 | 0.9% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.